Expression of immune system-associated antigens by c system: Relationship to the pathology of Alzheimer's di

Neurobiology of Aging 9, 339-349 DOI: 10.1016/s0197-4580(88)80079-4

Citation Report

#	Article	IF	CITATIONS
1	Immune actions in the nervous system: A brief review with special emphasis on Aalzheimer's disease. Drug Development Research, 1988, 15, 227-235.	1.4	27
2	Immune system associated antigens expressed by cells of the human central nervous system. Neuroscience Letters, 1988, 94, 17-22.	1.0	128
3	The neurophysiology of aging: Insights from new applications of old techniques. Neurobiology of Aging, 1988, 9, 601-605.	1.5	0
4	Immunologic and tissue culture approaches to the neurobiology of aging. Neurobiology of Aging, 1988, 9, 759-762.	1.5	14
5	Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neuroscience Letters, 1989, 107, 341-346.	1.0	370
6	Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. Journal of Neuroimmunology, 1989, 24, 173-182.	1.1	844
7	Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Research, 1989, 489, 247-253.	1.1	167
8	Potential Neurotrophic Factors in the Mammalian Central Nervous System: Functional Significance in the Developing and Aging Brain. International Review of Neurobiology, 1990, 32, 141-174.	0.9	44
9	Microglia in cerebellar plaques in Alzheimer's disease. Acta Neuropathologica, 1990, 80, 493-498.	3.9	100
10	Occurrence of diffuse amyloid deposits in the presubicular parvopyramidal layer in Alzheimer's disease. Acta Neuropathologica, 1990, 79, 537-544.	3.9	30
11	Antibodies to viral antigens, xenoantigens, and autoantigens in alzheimer's disease. Journal of Clinical Laboratory Analysis, 1990, 4, 367-375.	0.9	39
12	Anti-inflammatory drugs and Alzheimer disease. Lancet, The, 1990, 335, 1037.	6.3	423
13	Cholinergic modulation of aged-like retention deficits in young autoimmune mice. International Journal of Developmental Neuroscience, 1990, 8, 679-687.	0.7	3
14	Demonstrating immune-related antigens in Alzheimer's disease brain tissue. Neurobiology of Aging, 1990, 11, 477-479.	1.5	16
15	Brain microglia constitutively express β-2 integrins. Journal of Neuroimmunology, 1990, 30, 81-93.	1.1	415
16	Animal models of age-related dementia: neurobehavioral dysfunctions in autoimmune mice. Brain Research Bulletin, 1990, 25, 503-516.	1.4	14
17	Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron, 1990, 5, 831-839.	3.8	330
18	Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. Experimental Neurology, 1990, 110, 93-104.	2.0	169

#	Article	IF	Citations
19	Epidermal growth factor receptor expression in demented and aged human brain. Brain Research, 1990, 512, 347-352.	1.1	36
20	Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: implications for leakage across the blood-brain barrier in Alzheimer's disease. Brain Research, 1990, 516, 349-353.	1.1	81
21	Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease. Brain Research, 1990, 523, 273-280.	1.1	167
22	Cephaloconiosis: A free radical perspective on the proposed particulate-induced etiopathogenesis of alzheimer's dementia and related disorders. Medical Hypotheses, 1991, 34, 209-219.	0.8	21
23	Antibodies in the cerebrospinal fluid of some Alzheimer's disease patients recognize amoeboid microglial cells in the developing rat central nervous system. Neuroscience, 1991, 41, 739-752.	1.1	40
24	Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Research, 1991, 544, 315-319.	1.1	105
25	Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue. Journal of Neuroimmunology, 1991, 32, 19-28.	1.1	119
26	Antibody in the CSF of patients with multiple system atrophy reacts specifically with rat locus ceruleus. Journal of the Neurological Sciences, 1991, 106, 96-104.	0.3	17
27	Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer's disease. Journal of the Neurological Sciences, 1991, 106, 105-111.	0.3	116
28	Autoimmunity and Cognitive Decline in Aging and Alzheimer's Disease. , 1991, , 709-748.		8
29	Inoculation Study of Alzheimer Buffy Coat into Hamster Brain. Dementia and Geriatric Cognitive Disorders, 1991, 2, 57-63.	0.7	0
30	Reactions of the Immune System in Chronic Degenerative Neurological Diseases. Canadian Journal of Neurological Sciences, 1991, 18, 376-379.	0.3	81
31	Characterization of Intracytoplasmic Neurofilament Accumulation in Hamster Brain Caused by Alzheimer Buffy Coat Inoculation: Comparison with Experimental Neurofibrillary Changes Produced by Aluminum Intoxication. Gerontology, 1991, 37, 31-42.	1.4	5
32	New Biochemical Insights to Unravel the Pathogenesis of Alzheimer's Lesions. Canadian Journal of Neurological Sciences, 1991, 18, 408-410.	0.3	10
33	Effects of injected Alzheimer beta-amyloid cores in rat brain Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 8362-8366.	3.3	245
34	Interleukinâ€⊋ receptor in peripheral blood lymphocytes of Alzheimer's disease patients. Acta Psychiatrica Scandinavica, 1991, 84, 262-265.	2.2	15
35	Immune systemâ€associated antigens on the surface of peripheral blood lymphocytes in patients with Alzheimer's disease. Acta Psychiatrica Scandinavica, 1991, 83, 444-448.	2.2	32
36	Identification and distribution of microglial cells in the cerebral cortex of the lizard: A histochemical study. Journal of Comparative Neurology, 1991, 311, 434-444.	0.9	30

ARTICLE IF CITATIONS # Autoimmune mice as models for discovery of drugs against age-related dementia. Drug Development 37 1.4 7 Research, 1991, 24, 1-27. Increased senile plaques without microglia in Alzheimer's disease. Acta Neuropathologica, 1991, 81, 38 242-247. Immune Responses in Brains of Alzheimer's and Parkinson's Disease Patients: Hypothesis and Reality. 39 1.4 23 Reviews in the Neurosciences, 1992, 3, 79-98. Protein Kinases and Growth Associated Proteins in Plaque Formation in Alzheimer's Disease. Reviews in the Neurosciences, 1992, 3, 99-108. Cerebrospinal fluid antibodies : an indicator for immune responses in alzheimer's disease. Research in 41 0.9 7 Immunology, 1992, 143, 663-667. Activated microglia and cerebral amyloid deposits in alzheimer's disease. Research in Immunology, 1992, 143, 646-649. Astroglia in Alzheimer's disease. Neurobiology of Aging, 1992, 13, 239-253. 43 1.5 111 Complement activation and \hat{l}^2 -amyloid-mediated neurotoxicity in Alzheimer's disease. Research in 44 76 Immunology, 1992, 143, 624-630. Acute phase proteins but not activated microglial cells are present in parenchymal deposits in the 45 brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neuroscience 1.0 27 Letters, 1992, 140, 137-140. The decrease of CD8-positive lymphocytes in Alzheimer's disease. Journal of the Neurological Sciences, 1992, 107, 160-165. Characteristics of Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease 48 2.2 14 and age-matched controls. Mechanisms of Ageing and Development, 1992, 63, 105-116. Humoral and Cellular Immunologic Repertoire in Alzheimer's Disease. Annals of the New York Academy 49 1.8 of Sciences, 1992, 663, 349-356. \hat{l}^2 -Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques 50 1.1 298 in Alzheimer's disease. Brain Research, 1992, 569, 141-145. Human serum stimulates alzheimer markers in cultured hippocampal neurons. Journal of Neuroscience Research, 1992, 33, 355-369. 1.3 MHC class II-positive microglia in human brain: Association with alzheimer lesions. Journal of 52 1.3 196 Neuroscience Research, 1992, 33, 549-558. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's 2.5 828 disease. Glia, 1993, 7, 75-83. Microglia in degenerative neurological disease. Glia, 1993, 7, 84-92. 54 2.5574 Interleukin-4 and -5 as modulators of nerve growth factor synthesis/secretion in astrocytes. Journal 1.3 of Neuroscience Research, 1993, 34, 539-545.

#	Article	IF	Citations
56	Interleukin-2 as a neurotrophic factor for supporting the survival of neurons cultured from various regions of fetal rat brain. Journal of Neuroscience Research, 1993, 35, 305-311.	1.3	80
57	Heat shock protein (hsx70) mRNA expression in human brain: effects of neurodegenerative disease and agonal state. Neuropathology and Applied Neurobiology, 1993, 19, 10-21.	1.8	54
58	Immunohistochemical study of α2 Macroglobulin receptor in Alzheimer and control postmortem human brain. Molecular and Chemical Neuropathology, 1993, 18, 153-160.	1.0	75
59	β-Amyloid peptides induce degeneration of cultured rat microglia. Brain Research, 1993, 624, 121-125.	1.1	81
60	Trophic effects of interleukin-4, -7 and -8 on hippocampal neuronal cultures: potential involvement of glial-derived factors. Brain Research, 1993, 600, 49-55.	1.1	254
61	Cerebrospinal fluid microglial antibodies: Potential diagnostic markers for immune mechanisms in Alzheimer's disease. Behavioural Brain Research, 1993, 57, 225-234.	1.2	18
62	Systemic interleukin-1β decreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation. Neuroscience, 1993, 53, 297-301.	1.1	142
63	Microglia-derived plasminogen enhances neurite outgrowth from explant cultures of rat brain. International Journal of Developmental Neuroscience, 1993, 11, 227-237.	0.7	55
64	Induction of class I major histocompatibility complex antigens on adult primate retinal neurons. Journal of Neuroimmunology, 1993, 43, 45-57.	1.1	14
65	The Immunopathology of Alzheimer's Disease and Some Related Disorders. Brain Pathology, 1993, 3, 333-347.	2.1	79
66	Antihistone and anti-dsDNA autoantibodies in Alzheimer's disease and vascular dementia. Biological Psychiatry, 1993, 34, 380-385.	0.7	23
67	Principles of Control and Selection in Mammalian Aging. Gerontology, 1994, 40, 307-313.	1.4	1
68	The SEC Receptor: A Possible Link between Neonatal Hepatitis in α1 -Antitrypsin Deficiency and Alzheimer's Disease. Pediatric Research, 1994, 36, 271-277.	1.1	16
69	Transforming growth factor-β protects human neurons against β-amyloid-induced injury. Molecular and Chemical Neuropathology, 1994, 23, 159-178.	1.0	74
70	Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid plaques in Alzheimer's disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1994, 424, 421-427.	1.4	74
71	Vascular basement membrane components and the lesions of Alzheimer's disease: Light and electron microscopic analyses. Microscopy Research and Technique, 1994, 28, 204-215.	1.2	43
72	Alzheimer's disease cerebrospinal fluid antibodies display selectivity for microglia. Molecular Neurobiology, 1994, 9, 41-54.	1.9	21
73	Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. Journal of the Neurological Sciences, 1994, 121, 46-49.	0.3	113

#	Article	IF	CITATIONS
74	α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease. Neurobiology of Aging, 1994, 15, 313-317.	1.5	91
75	Targets for Alzheimer's disease research: From basic mechanisms to rational therapies. Neurobiology of Aging, 1994, 15, 157-160.	1.5	Ο
76	Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Research, 1994, 645, 78-84.	1.1	105
77	Research on Alzheimer's disease in Japan: a personal view on history and present status. Archives of Gerontology and Geriatrics, 1994, 19, 89-104.	1.4	2
78	Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: Selective effects on specific interleukins and interleukin receptors. Neuroscience, 1994, 61, 745-754.	1.1	103
79	The pathophysiology of reactive oxygen intermediates in the central nervous system. Medical Hypotheses, 1994, 43, 223-230.	0.8	41
80	Mechanisms of sprouting in the adult central nervous system: Cellular responses in areas of terminal degeneration and reinnervation in the rat hippocampus. Neuroscience, 1994, 58, 705-725.	1.1	95
81	Inflammation and Alzheimer's Disease. CNS Drugs, 1994, 1, 241-244.	2.7	5
82	ALZHEIMER'S AS A COMMON COMPLEX DISEASE. Canadian Journal of Neurological Sciences, 1994, 21, 78-78.	0.3	0
83	Acidic FGF Expression in the Surroundings of Senile Plaques Tohoku Journal of Experimental Medicine, 1994, 174, 279-293.	0.5	16
84	Insulin-like growth factor-1 mRNA is increased in deafferented hippocampus: Spatiotemporal correspondence of a trophic event with axon sprouting. Journal of Comparative Neurology, 1995, 352, 147-160.	0.9	125
85	Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Research, 1995, 675, 75-82.	1.1	83
86	Microglial release of nitric oxide by the synergistic action of β-amyloid and IFN-γ. Brain Research, 1995, 692, 207-214.	1.1	167
88	Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology, 1995, 45, 51-55.	1.5	446
89	The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Research Reviews, 1995, 21, 195-218.	9.1	1,231
90	Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neuroscience Letters, 1995, 202, 17-20.	1.0	719
91	Differential effects of interleukin-1β and interleukin-2 on glia and hippocampal neurons in culture. International Journal of Developmental Neuroscience, 1995, 13, 201-212.	0.7	45
92	Amyloid β protein (Aβ) removal by neuroglial cells in culture. Neurobiology of Aging, 1995, 16, 737-745.	1.5	185

#	Article	IF	CITATIONS
93	β-Amyloid(25–35) induces the production of interleukin-8 from human monocytes. Journal of Neuroimmunology, 1995, 59, 29-33.	1.1	41
94	Interleukin-1 and nerve growth factor induce hypersecretion and hypersulfation of neuroblastoma proteoglycans which bind β-amyloid. Journal of Neuroimmunology, 1995, 60, 151-160.	1.1	7
95	Correlative transmission and scanning electron microscopy study of microglia activated by interferon-,y and tumor necrosis factor-cx in vitro. Pathology Research and Practice, 1995, 191, 1016-1022.	1.0	5
96	Inflammatory mechanisms and anti-inflammatory therapy in Alzheimer's disease. Neurobiology of Aging, 1996, 17, 669-671.	1.5	32
97	The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiology of Aging, 1996, 17, 673-680.	1.5	194
98	Inflammation and Alzheimer's disease pathogenesis. Neurobiology of Aging, 1996, 17, 681-686.	1.5	419
99	Evolutionary perspectives on amyloid and inflammatory features of Alzheimer disease. Neurobiology of Aging, 1996, 17, 809-815.	1.5	27
100	Expression of CD43 in human microglia and its downregulation in Alzheimer's disease. Journal of Neuroimmunology, 1996, 71, 81-86.	1.1	19
101	Do Nonsteroidal Anti-Inflammatory Drugs Have a Protective Effect Against Dementia?. Drugs and Aging, 1996, 9, 1-7.	1.3	11
102	Major Histocompatibility Class II Molecules in the CNS: Increased Microglial Expression at the Onset of Narcolepsy in a Canine Model. Journal of Neuroscience, 1996, 16, 4588-4595.	1.7	62
103	Specific Domains of β-Amyloid from Alzheimer Plaque Elicit Neuron Killing in Human Microglia. Journal of Neuroscience, 1996, 16, 6021-6037.	1.7	263
104	Enhanced Cytotoxic Response of Natural Killer Cells to Interleukin-2 in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1996, 7, 343-348.	0.7	13
105	Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Research, 1996, 712, 122-126.	1.1	133
106	Enhancement of immunoreactivity for NF-κB in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Research, 1996, 735, 159-168.	1.1	207
107	Microglial cerebrospinal fluid antibodies. Molecular and Chemical Neuropathology, 1996, 28, 89-95.	1.0	7
108	Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. , 1996, 16, 276-284.		239
109	Neuronal Expression of Class II Major Histocompatibility Complex (HLA-DR) in 2 Cases of Pick Disease. Archives of Neurology, 1997, 54, 243-248.	4.9	17
110	T-Cell Interferon Gamma Binding in Patients With Dementia of the Alzheimer Type. Archives of Neurology, 1997, 54, 457-462.	4.9	9

\sim			<u> </u>	
(1-	ΓΔΤΙ	ON	REPC	NDT
\sim			IVEL C	

#	Article	IF	CITATIONS
111	Excitatory Pattern of Gamma-Interferon on Natural Killer Cell Activity in Senile Dementia of the Alzheimer Type. Dementia and Geriatric Cognitive Disorders, 1997, 8, 308-313.	0.7	12
112	Microglial in Neurodegenerative Disorders: Emphasis on Alzheimer's Disease. Gerontology, 1997, 43, 95-108.	1.4	39
113	Chapter 3 Structural Changes in the Aged Brain. Advances in Cell Aging and Gerontology, 1997, , 51-76.	0.1	0
114	Distribution of Lymphocytes in Persons with Alzheimer's Disease (AD) as Compared to Age Matched Nondemented (ND) Control Subjects. Clinical Gerontologist, 1997, 18, 13-19.	1.2	1
115	Activation of nuclear factor-κB by β-amyloid peptides and interferon-γ in murine microglia. Journal of Neuroimmunology, 1997, 77, 51-56.	1.1	110
116	A proposed new strategy of immunotherapy for Alzheimer's disease. Medical Hypotheses, 1997, 49, 319-326.	0.8	8
117	Immunological Alterations in Alzheimer�s Disease: Antimicroglia Antibodies in Sera of Alzheimer Patients. , 1997, 18, 108-113.		1
118	Properties of the pore-forming P2X7 purinoceptor in mouse NTW8 microglial cells. British Journal of Pharmacology, 1997, 121, 1429-1437.	2.7	123
119	Bcl-xl-Specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states. Journal of Neuroscience Research, 1997, 47, 98-108.	1.3	50
120	Expression of differential immune factors in temporal cortex and cerebellum: The role of ?-1-antichymotrypsin, apolipoprotein E, and reactive glia in the progression of Alzheimer's disease. Journal of Comparative Neurology, 1998, 396, 511-520.	0.9	58
121	Transgenic Mouse Models of Alzheimer's Disease and Amyotrophic Lateral Sclerosis. Brain Pathology, 1998, 8, 735-757.	2.1	27
122	Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions. Journal of Neuroscience Research, 1998, 54, 1-6.	1.3	171
123	The cerebrospinal fluid oxidized NO metabolites, nitrite and nitrate, in Alzheimer's disease and vascular dementia of Binswanger type and multiple small infarct type. Journal of Neural Transmission, 1998, 105, 1283-1291.	1.4	37
124	Constitutive and visna virus induced expression of class I and II major histocompatibility complex antigens in the central nervous system of sheep and their role in the pathogenesis of visna lesions. Neuropathology and Applied Neurobiology, 1998, 24, 224-232.	1.8	9
125	Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron/glia cultures. Journal of Neuroimmunology, 1998, 85, 1-10.	1.1	182
126	Microglial Expression of MHC Class II Increases in Normal Aging of Nonhuman Primates. Neurobiology of Aging, 1998, 19, 47-55.	1.5	223
127	ALZHEIMER'S DISEASE: Genetic Studies and Transgenic Models. Annual Review of Genetics, 1998, 32, 461-493.	3.2	384
128	MUTANT GENES IN FAMILIAL ALZHEIMER'S DISEASE AND TRANSGENIC MODELS. Annual Review of Neuroscience, 1998, 21, 479-505.	5.0	572

#	Article	IF	CITATIONS
129	Importance of Immunological and Inflammatory Processes in the Pathogenesis and THERAPY of Alzheimer's Disease. International Journal of Neuroscience, 1998, 95, 203-236.	0.8	49
130	Inflammation and Alzheimer's Disease: Relationships between Pathogenic Mechanisms and Clinical Expression. Experimental Neurology, 1998, 154, 89-98.	2.0	92
131	A role for the Â-amyloid precursor protein in memory?. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 12074-12076.	3.3	27
132	Chapter 24 Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice. Progress in Brain Research, 1998, 117, 327-334.	0.9	33
133	T-Lymphocyte Interleukin 6 Receptor Binding in Patients With Dementia of Alzheimer Type. Archives of Neurology, 1998, 55, 1305.	4.9	13
134	Decreased Immunosuppressive Effect of Cortisol on Natural Killer Cytotoxic Activity in Senile Dementia of the Alzheimer Type. Dementia and Geriatric Cognitive Disorders, 1998, 9, 149-156.	0.7	12
135	Aβ-Induced Proinflammatory Cytokine Release from Differentiated Human THP-1 Monocytes. , 2000, 32, 101-112.		2
136	Microglial reaction and neuronal death in the hippocampus of rat models of epilepsy. Neuropathology, 1999, 19, 203-208.	0.7	2
137	Alphaâ€synuclein in Lewy Body Disease and Alzheimer's Disease. Brain Pathology, 1999, 9, 707-720.	2.1	217
138	Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue. Acta Neuropathologica, 1999, 97, 383-392.	3.9	87
139	Estrogen and microglia: A regulatory system that affects the brain. , 1999, 40, 484-496.		135
140	Microglial Activation Resulting from CD40-CD40L Interaction After -Amyloid Stimulation. Science, 1999, 286, 2352-2355.	6.0	340
141	Nonsteroidal Anti-Inflammatory Drugs and Alzheimer??s Disease. CNS Drugs, 1999, 11, 207-224.	2.7	10
142	Menopause and estrogen deficiency as a risk factor in dementing illness: hypothesis on the biological basis. Maturitas, 1999, 31, 95-101.	1.0	22
143	Antimicroglia antibodies in sera of Alzheimer's disease patients. Biological Psychiatry, 1999, 45, 508-511.	0.7	7
144	Microglia in Alzheimer's Disease and Transgenic Models. American Journal of Pathology, 1999, 154, 1627-1631.	1.9	35
145	Dehydroepiandrosterone Sulfate Decreases the Interleukin-2-Mediated Overactivity of the Natural Killer Cell Compartment in Senile Dementia of the Alzheimer Type. Dementia and Geriatric Cognitive Disorders, 1999, 10, 21-27.	0.7	34
146	Structural and functional evidence for microglial expression of C1qRP, the C1q receptor that enhances phagocytosis. Journal of Leukocyte Biology, 2000, 67, 109-116.	1.5	71

#	Article	IF	Citations
147	Increase in HLA-DR Immunoreactive Microglia in Frontal and Temporal Cortex of Chronic Schizophrenics. Journal of Neuropathology and Experimental Neurology, 2000, 59, 137-150.	0.9	294
148	Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease. European Journal of Neuroscience, 2000, 12, 1900-1912.	1.2	55
149	Interface between Vascular Dementia and Alzheimer Syndrome: Nosologic Redefinition. Annals of the New York Academy of Sciences, 2000, 903, 229-238.	1.8	11
150	Unregulated inflammation shortens human functional longevity. Inflammation Research, 2000, 49, 561-570.	1.6	81
151	L-Glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. Journal of Neural Transmission, 2000, 107, 183-189.	1.4	51
152	Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia. Journal of Neuroscience, 2000, 20, 6309-6316.	1.7	801
153	Positive Modulation of AMPA Receptors Increases Neurotrophin Expression by Hippocampal and Cortical Neurons. Journal of Neuroscience, 2000, 20, 8-21.	1.7	262
154	Cortical Inflammation in Alzheimer Disease but Not Dementia With Lewy Bodies. Archives of Neurology, 2000, 57, 817.	4.9	67
155	Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease. Archives of Neurology, 2000, 57, 831.	4.9	69
156	Complement Component C1q Modulates the Phagocytosis of Aβ by Microglia. Experimental Neurology, 2000, 161, 127-138.	2.0	115
157	The cause of neuronal degeneration in Alzheimer's disease. Progress in Neurobiology, 2000, 60, 139-165.	2.8	226
158	Inflammation and Alzheimer's disease. Neurobiology of Aging, 2000, 21, 383-421.	1.5	4,069
159	Alzheimer's disease: An inflammatory disease?. Neurobiology of Aging, 2000, 21, 433-436.	1.5	33
160	Aged Mice Exhibit Greater Mortality Concomitant to Increased Brain and Plasma TNF-α Levels following Intracerebroventricular Injection of Lipopolysaccharide. Gerontology, 2000, 46, 115-128.	1.4	46
161	Cellular and molecular mechanisms of Alzheimerâ \in Ms disease inflammation. , 2001, , 3-49.		0
162	Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease. Neurochemistry International, 2001, 39, 333-340.	1.9	223
163	Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochemistry International, 2001, 39, 381-391.	1.9	179
164	Inflammation, autotoxicity and Alzheimer disease. Neurobiology of Aging, 2001, 22, 799-809.	1.5	452

#	Article	IF	CITATIONS
165	The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiology of Aging, 2001, 22, 923-930.	1.5	79
166	Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiology of Aging, 2001, 22, 945-956.	1.5	147
167	Chronic inflammation in Alzheimer's disease offers therapeutic opportunities. Expert Review of Neurotherapeutics, 2001, 1, 53-60.	1.4	14
168	Molecular and cellular mediators of Alzheimer's disease inflammation. Journal of Alzheimer's Disease, 2001, 3, 131-157.	1.2	48
169	Activation Mechanism of Brain Microglia in Patients With Diffuse Neurofibrillary Tangles With Calcification: A Comparison With Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2001, 15, 45-50.	0.6	9
170	Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease. Archives of Neurology, 2001, 58, 517-a-518.	4.9	10
171	Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative Post-translational Modification of Amyloid Deposits. , 0, , 341-361.		14
172	Early formation of mature amyloid-? protein deposits in a mutant APP transgenic model depends on levels of A?1-42. Journal of Neuroscience Research, 2001, 66, 573-582.	1.3	226
173	IL-4, IL-10 and IL-13 modulate Aβ(1–42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. Journal of Neuroimmunology, 2001, 113, 49-62.	1.1	240
174	Microglial Activation parallels System Degeneration in progressive Supranuclear palsy and Corticobasal Degeneration. Journal of Neuropathology and Experimental Neurology, 2001, 60, 647-657.	0.9	176
175	Microglia at brain stab wounds express connexin 43 and in vitro form functional gap junctions after treatment with interferon-Â and tumor necrosis factor-Â. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 4190-4195.	3.3	213
176	Effect of Phosphodiesterase Inhibitors on Nitric Oxide Production by Glial Cells Tohoku Journal of Experimental Medicine, 2002, 196, 167-177.	0.5	16
177	Acute Neuroinflammation Exacerbates Excitotoxicity in Rat Hippocampus in Vivo. Experimental Neurology, 2002, 177, 95-104.	2.0	44
178	Senile plaque composition and posttranslational modification of amyloid-l ² peptide and associated proteins. Peptides, 2002, 23, 1343-1350.	1.2	133
179	Neutrophils CD11b and fibroblasts PGE2 are elevated in Alzheimer's disease. Neurobiology of Aging, 2002, 23, 523-530.	1.5	53
180	Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends in Neurosciences, 2002, 25, 313-319.	4.2	423
181	Neuroinflammation in Neurodegeneration: Lessons from Alzheimer's Disease. , 0, , 283-294.		0
182	Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. Journal of Neuroimmunology, 2002, 124, 83-92.	1.1	394

#	Article	IF	CITATIONS
183	Immune response gene expression increases in the aging murine hippocampus. Journal of Neuroimmunology, 2002, 132, 99-112.	1.1	102
184	Identification of second messengers that induce expression of functional gap junctions in microglia cultured from newborn rats. Brain Research, 2002, 943, 191-201.	1.1	43
185	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia, 2002, 39, 148-161.	2.5	124
186	Microglia and inflammatory mechanisms in the clearance of amyloid ? peptide. Clia, 2002, 40, 260-269.	2.5	350
187	p38 MAP Kinase Is Involved in Lipopolysaccharideâ€Induced Dopaminergic Neuronal Cell Death in Rat Mesencephalic Neuronâ€Glia Cultures. Annals of the New York Academy of Sciences, 2002, 962, 332-346.	1.8	56
188	Gö6976 Protects Mesencephalic Neurons from Lipopolysaccharideâ€Elicited Death by Inhibiting p38 MAP Kinase Phosphorylation. Annals of the New York Academy of Sciences, 2002, 962, 347-359.	1.8	14
189	Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathologica, 2003, 106, 518-526.	3.9	619
190	Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Research, 2003, 964, 288-294.	1.1	141
191	Brain immune responses cognitive decline and dementia: relationship with phenotype expression and genetic background. Mechanisms of Ageing and Development, 2003, 124, 539-548.	2.2	37
192	P2X7 nucleotide receptor activation enhances IFNÎ ³ -induced type II nitric oxide synthase activity in BV-2 microglial cells. Journal of Neurochemistry, 2003, 87, 344-352.	2.1	89
193	Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 1-7.	1.3	1,019
194	Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Progress in Neurobiology, 2003, 71, 83-248.	2.8	176
195	Inflammatory processes in Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 741-749.	2.5	445
196	Temporal and sequential analysis of microglia in the substantia nigra following medial forebrain bundle axotomy in rat. Neuroscience, 2003, 116, 925-933.	1.1	49
197	Effects of estrogen and raloxifene on neuroglia number and morphology in the hippocampus of aged female mice. Neuroscience, 2003, 121, 659-666.	1.1	96
198	Soluble Factors Released by Toxoplasma gondii -Infected Astrocytes Down-Modulate Nitric Oxide Production by Gamma Interferon-Activated Microglia and Prevent Neuronal Degeneration. Infection and Immunity, 2003, 71, 2047-2057.	1.0	73
199	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. Journal of Leukocyte Biology, 2003, 73, 155-164.	1.5	122
200	Cerebrospinal fluid and serum antimicroglial antibodies: prospects for early diagnosis of Alzheimer′s disease. Expert Review of Neurotherapeutics, 2003, 3, 247-257.	1.4	3

#	Article	IF	Citations
201	Amyloid β peptide-induced corpus callosum damage and glial activation in vivo. NeuroReport, 2003, 14, 1429-1433.	0.6	65
202	Microglial Activation Parallels System Degeneration in Multiple System Atrophy. Journal of Neuropathology and Experimental Neurology, 2004, 63, 43-52.	0.9	147
203	Cells of monocyte/microglial lineage are involved in both microvessel amyloidosis and fibrillar plaque formation in APPsw tg mice. Brain Research, 2004, 1022, 19-29.	1.1	49
204	Inhibitory action of minocycline on lipopolysaccharide-Induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Archives of Pharmacal Research, 2004, 27, 314-318.	2.7	79
205	Dystrophic microglia in the aging human brain. Glia, 2004, 45, 208-212.	2.5	567
206	Microglia and Alzheimer's disease pathogenesis. Journal of Neuroscience Research, 2004, 77, 1-8.	1.3	299
207	Alzheimer's disease and immune activation: A translational perspective. Neuroscience Research Communications, 2004, 35, 193-201.	0.2	2
208	The Significance of Vasoactive Intestinal Peptide in Immunomodulation. Pharmacological Reviews, 2004, 56, 249-290.	7.1	375
209	Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid-β. Biochemistry, 2004, 43, 560-568.	1.2	362
210	Welcome to the Journal of Neuroinflammation!. Journal of Neuroinflammation, 2004, 1, 1.	3.1	26
211	Prevalence of cognitive disorders differs as a function of age in HIV virus infection. Aids, 2004, 18, 11-18.	1.0	164
212	Chronic intracerebroventricular infusion of lipopolysaccharide: effects of ibuprofen treatment and behavioural and histopathological correlates. Behavioural Pharmacology, 2005, 16, 531-541.	0.8	21
213	Proteases and Alzheimer's Disease: Present Knowledge and Emerging Concepts of Therapy. , 2005, , 1-23.		5
214	T-Cells in Alzheimer's Disease. NeuroMolecular Medicine, 2005, 7, 255-264.	1.8	167
215	Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. Journal of Neuroscience Research, 2005, 81, 412-425.	1.3	84
216	NeuroAIDS: Contributions of the human immunodeficiency virus-1 proteins tat and gp120 as well as CD40 to microglial activation. Journal of Neuroscience Research, 2005, 81, 436-446.	1.3	65
217	Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-α and estrogen receptor-β in microglia. Journal of Neuroscience Research, 2005, 81, 653-665.	1.3	104
218	The Dualistic Nature of Immune Modulation In Alzheimers Disease: Lessons from the Transgenic Models. Current Pharmaceutical Design, 2005, 11, 3335-3352.	0.9	3

#	Article	IF	CITATIONS
219	Mechanisms of Cell Signaling and Inflammation in Alzheimers Disease. Inflammation and Allergy: Drug Targets, 2005, 4, 247-256.	3.1	165
220	Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. Journal of Leukocyte Biology, 2005, 78, 1192-1197.	1.5	173
221	Reciprocal Activity of Ginsenosides in the Production of Proinflammatory Repertoire, and their Potential Roles in Neuroprotectionin vitro. Planta Medica, 2005, 71, 476-481.	0.7	62
222	3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Attenuate Â-Amyloid-Induced Microglial Inflammatory Responses. Journal of Neuroscience, 2005, 25, 299-307.	1.7	164
223	Dynamic Complexity of the Microglial Activation Response in Transgenic Models of Amyloid Deposition: Implications for Alzheimer Therapeutics. Journal of Neuropathology and Experimental Neurology, 2005, 64, 743-753.	0.9	166
224	Cytokines and Brain. , 2005, , 41-80.		1
225	The regulation of pro-inflammatory gene expression induced by pigment epithelium-derived factor in rat cultured microglial cells. Neuroscience Letters, 2005, 380, 105-110.	1.0	26
226	Microglia and neuroprotection: implications for Alzheimer's disease. Brain Research Reviews, 2005, 48, 234-239.	9.1	219
227	Microglial responses to amyloid beta peptide opsonization and indomethacin treatment. Journal of Neuroinflammation, 2005, 2, 18.	3.1	25
228	Matrix Metalloproteinase-3: A Novel Signaling Proteinase from Apoptotic Neuronal Cells That Activates Microglia. Journal of Neuroscience, 2005, 25, 3701-3711.	1.7	241
229	Exaggerated neuroinflammation and sickness behavior in aged mice after activation of the peripheral innate immune system. FASEB Journal, 2005, 19, 1329-1331.	0.2	733
231	mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiology of Aging, 2006, 27, 717-722.	1.5	291
232	Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Neuroscience, 2006, 140, 67-76.	1.1	84
233	Genetically Engineered Mouse Models of Neurodegenerative Disorders. , 2006, , 371-408.		0
234	Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years. Journal of Alzheimer's Disease, 2006, 9, 271-276.	1.2	225
235	Reactive Macrophages Increase Oxidative Stress and Alpha-Synuclein Nitration During Death of Dopaminergic Neuronal Cells in Co-Culture: Relevance to Parkinson's Disease. Neurochemical Research, 2006, 31, 85-94.	1.6	72
236	Alzheimer's disease, brain immune privilege and memory: a hypothesis. Journal of Neural Transmission, 2006, 113, 1697-1707.	1.4	22
237	The significance of neuroinflammation in understanding Alzheimer's disease. Journal of Neural Transmission, 2006, 113, 1685-1695.	1.4	243

#	Article	IF	CITATIONS
238	Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathologica, 2006, 112, 305-316.	3.9	199
239	Alpha-tocopherol (vitamin E) induces rapid, nonsustained proliferation in cultured rat microglia. Clia, 2006, 53, 669-674.	2.5	23
240	Cerebrolysin decreases amyloid-β production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. Journal of Neuroscience Research, 2006, 83, 1252-1261.	1.3	98
241	Microglia in the Aging Brain. Journal of Neuropathology and Experimental Neurology, 2006, 65, 199-203.	0.9	294
242	Impaired regulation of immune responses in cognitive decline and Alzheimer's disease: lessons from genetic association studies. Expert Review of Neurotherapeutics, 2006, 6, 1327-1336.	1.4	11
243	Anti-Inflammatory Drugs in the Treatment of Neurodegenerative Diseases: Current State. Current Pharmaceutical Design, 2006, 12, 3509-3519.	0.9	45
244	Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease. Current Pharmaceutical Design, 2006, 12, 719-738.	0.9	29
245	Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions. Current Neuropharmacology, 2007, 5, 232-243.	1.4	55
246	Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator. Current Pharmaceutical Design, 2007, 13, 1113-1139.	0.9	80
247	Systemic and Acquired Immune Responses in Alzheimer's Disease. International Review of Neurobiology, 2007, 82, 205-233.	0.9	88
248	Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. Journal of Clinical Investigation, 2007, 117, 1595-1604.	3.9	357
249	Hematopoietic Prostaglandin D Synthase and DP1 Receptor Are Selectively Upregulated in Microglia and Astrocytes Within Senile Plaques From Human Patients and in a Mouse Model of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2007, 66, 469-480.	0.9	78
250	Peripheral T cells overexpress MIP-1α to enhance its transendothelial migration in Alzheimer's disease. Neurobiology of Aging, 2007, 28, 485-496.	1.5	119
251	NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiology of Aging, 2007, 28, 639-647.	1.5	454
252	Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiology of Aging, 2007, 28, 1821-1833.	1.5	186
253	Inhibition of gene expression and production of iNOS and TNF-α in LPS-stimulated microglia by methanol extract of Phellodendri cortex. International Immunopharmacology, 2007, 7, 955-962.	1.7	39
254	Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3Â Signaling Pathway in a Transgenic Model of Alzheimer's Disease Are Associated with Reduced Amyloid Precursor Protein Phosphorylation. Journal of Neuroscience, 2007, 27, 1981-1991.	1.7	265
255	Neuroinflammation in Alzheimer's Disease and Parkinson's Disease: Are Microglia Pathogenic in Either Disorder?. International Review of Neurobiology, 2007, 82, 235-246.	0.9	225

#	Article	IF	CITATIONS
256	Cajal's Contributions to the Study of Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 12, 161-174.	1.2	28
257	Aging, Neuroinflammation, and Behavior. , 2007, , 379-391.		1
258	Clial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Clia as a Potential Therapeutic Target. Current Signal Transduction Therapy, 2007, 2, 77-90.	0.3	5
260	The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients. Human Psychopharmacology, 2007, 22, 75-80.	0.7	13
261	Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience, 2007, 8, 57-69.	4.9	3,477
262	Molecular and cellular characterization of the ageâ€related neuroinflammatory processes occurring in normal rat hippocampus: potential relation with the loss of somatostatin GABAergic neurons. Journal of Neurochemistry, 2007, 103, 984-996.	2.1	67
263	Cerebrospinal fluid antimicroglial antibodies in Alzheimer disease: A putative marker of an ongoing inflammatory process. Experimental Gerontology, 2007, 42, 355-363.	1.2	13
264	Altered lymphocyte distribution in Alzheimer's disease. Journal of Psychiatric Research, 2007, 41, 174-178.	1.5	145
265	Transgenic animal models of neurodegenerative diseases and their application to treatment developmenta <code>^†</code> . Advanced Drug Delivery Reviews, 2007, 59, 1093-1102.	6.6	77
266	Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. Acta Neuropathologica, 2007, 114, 243-254.	3.9	20
267	New developments in understanding and treating neuroinflammation. Journal of Molecular Medicine, 2008, 86, 975-985.	1.7	40
268	Vitamin E increases S100Bâ€mediated microglial activation in an S100Bâ€overexpressing mouse model of pathological aging. Glia, 2008, 56, 1780-1790.	2.5	24
269	CB ₂ receptors in the brain: role in central immune function. British Journal of Pharmacology, 2008, 153, 240-251.	2.7	274
270	Inflammation, genes and zinc in Alzheimer's disease. Brain Research Reviews, 2008, 58, 96-105.	9.1	97
271	Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide. Journal of Psychiatric Research, 2008, 42, 151-157.	1.5	678
272	The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. Journal of Neuroinflammation, 2008, 5, 7.	3.1	418
273	Cannabinoids and the Brain. , 2008, , .		8
274	Aging sensitizes mice to behavioral deficits induced by central HIV-1 gp120. Neurobiology of Aging, 2008, 29, 614-621.	1.5	63

#	Article	IF	CITATIONS
275	Autoantibody-mediated neuroinflammation: Pathogenesis of neuropsychiatric systemic lupus erythematosus in the NZM88 murine model. Brain, Behavior, and Immunity, 2008, 22, 949-959.	2.0	34
276	Neprilysin: An Enzyme Candidate to Slow the Progression of Alzheimer's Disease. American Journal of Pathology, 2008, 172, 1342-1354.	1.9	157
277	Blueberry Opposes <i>β</i> -Amyloid Peptide-Induced Microglial Activation Via Inhibition of p44/42 Mitogen-Activation Protein Kinase. Rejuvenation Research, 2008, 11, 891-901.	0.9	45
278	Biology and Neuropathology of Dementia in Syphilis and Lyme Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 825-844.	1.0	34
279	Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2008, 8, 159-172.	0.6	51
280	IL-4-Induced Selective Clearance of Oligomeric β-Amyloid Peptide1–42 by Rat Primary Type 2 Microglia. Journal of Immunology, 2008, 181, 6503-6513.	0.4	130
281	The Inflammatory Response in Alzheimer's Disease. Journal of Periodontology, 2008, 79, 1535-1543.	1.7	76
282	Anti-Selectin Therapy for the Treatment of Inflammatory Diseases. Inflammation and Allergy: Drug Targets, 2008, 7, 85-93.	1.8	54
283	Juzen-taiho-to, an Herbal Medicine, Activates and Enhances Phagocytosis in Microglia/Macrophages. Tohoku Journal of Experimental Medicine, 2008, 215, 43-54.	0.5	19
284	Non-Steroidal Anti-Inflammatory Drugs as Anti-Amyloidogenic Compounds. Current Pharmaceutical Design, 2008, 14, 3280-3294.	0.9	30
285	Amyloid Î ² Interaction with Receptor for Advanced Glycation End Products Up-Regulates Brain Endothelial CCR5 Expression and Promotes T Cells Crossing the Blood-Brain Barrier. Journal of Immunology, 2009, 182, 5778-5788.	0.4	104
286	Toll-Like Receptors in Alzheimer's Disease. Current Topics in Microbiology and Immunology, 2009, 336, 137-153.	0.7	146
287	PKR, the double stranded RNAâ€dependent protein kinase as a critical target in Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2009, 13, 1476-1488.	1.6	39
288	Autoimmune pathology accounts for common manifestations in a wide range of neuro-psychiatric disorders: The olfactory and immune system interrelationship. Clinical Immunology, 2009, 130, 235-243.	1.4	73
289	Variations in the neuropathology of familial Alzheimer's disease. Acta Neuropathologica, 2009, 118, 37-52.	3.9	112
290	Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathologica, 2009, 118, 475-485.	3.9	584
291	Current Hypotheses and Research Milestones in Alzheimer's Disease. , 2009, , .		4
292	Central inhibition of interleukin- $1\hat{l}^2$ ameliorates sickness behavior in aged mice. Brain, Behavior, and Immunity, 2009, 23, 396-401.	2.0	71

#	Article	IF	CITATIONS
293	Amyloid β peptide promotes differentiation of pro-inflammatory human myeloid dendritic cells. Neurobiology of Aging, 2009, 30, 210-221.	1.5	21
294	Interferon-Î ³ -dependent cytotoxic activation of human astrocytes and astrocytoma cells. Neurobiology of Aging, 2009, 30, 1924-1935.	1.5	79
295	Immune Activation in Brain Aging and Neurodegeneration: Too Much or Too Little?. Neuron, 2009, 64, 110-122.	3.8	594
296	Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Review of Neurotherapeutics, 2009, 9, 1059-1071.	1.4	178
297	Common Pathological Processes and Transcriptional Pathways in Alzheimer's Disease and Type 2 Diabetes. Journal of Alzheimer's Disease, 2009, 16, 787-808.	1.2	49
299	Can peripheral leukocytes be used as Alzheimer's disease biomarkers?. Expert Review of Neurotherapeutics, 2009, 9, 1623-1633.	1.4	34
300	Functional Genomics of Brain Aging and Alzheimers Disease: Focus on Selective Neuronal Vulnerability. Current Genomics, 2010, 11, 618-633.	0.7	81
301	Neuroinflammation in Alzheimer's Disease: Mechanisms, Pathologic Consequences, and Potential for Therapeutic Manipulation. Journal of Alzheimer's Disease, 2010, 21, 1-14.	1.2	209
302	Infiltration of T Lymphocytes and Expression of ICAM-1 in the Hippocampus of Patients with Hippocampal Sclerosis. Acta Histochemica Et Cytochemica, 2010, 43, 157-162.	0.8	33
	······································		
303	Systemic Inflammation and Cognition in the Elderly. , 2010, , 177-198.		1
303 304		1.2	1 92
	Systemic Inflammation and Cognition in the Elderly. , 2010, , 177-198. APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant	1.2	
304	Systemic Inflammation and Cognition in the Elderly. , 2010, , 177-198. APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Structure and Function, 2010, 214, 111-126.		92
304 305	Systemic Inflammation and Cognition in the Elderly. , 2010, , 177-198. APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Structure and Function, 2010, 214, 111-126. Microglial Activation and Chronic Neurodegeneration. Neurotherapeutics, 2010, 7, 354-365. Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering	2.1	92 747
304 305 306	Systemic Inflammation and Cognition in the Elderly. , 2010, , 177-198. APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Structure and Function, 2010, 214, 111-126. Microglial Activation and Chronic Neurodegeneration. Neurotherapeutics, 2010, 7, 354-365. Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation. Pharmaceuticals, 2010, 3, 1812-1841. Why Alzheimer's Disease Starts with a Memory Impairment: Neurophysiological Insight, Journal of	2.1 1.7	92 747 71
304 305 306 307	Systemic Inflammation and Cognition in the Elderly., 2010, , 177-198. APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Structure and Function, 2010, 214, 111-126. Microglial Activation and Chronic Neurodegeneration. Neurotherapeutics, 2010, 7, 354-365. Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation. Pharmaceuticals, 2010, 3, 1812-1841. Why Alzheimer's Disease Starts with a Memory Impairment: Neurophysiological Insight. Journal of Alzheimer's Disease, 2010, 20, 5-16. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Human Molecular Genetics, 2010,	2.1 1.7 1.2	92 747 71 23
304 305 306 307 308	Systemic Inflammation and Cognition in the Elderly. , 2010, , 177-198. APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Structure and Function, 2010, 214, 111-126. Microglial Activation and Chronic Neurodegeneration. Neurotherapeutics, 2010, 7, 354-365. Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation. Pharmaceuticals, 2010, 3, 1812-1841. Why Alzheimer's Disease Starts with a Memory Impairment: Neurophysiological Insight. Journal of Alzheimer's Disease, 2010, 20, 5-16. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Human Molecular Genetics, 2010, 19, R12-R20. Systemic Immune Responses in Alzheimer's Disease: In Vitro Mononuclear Cell Activation and Cytokine	2.1 1.7 1.2 1.4	 92 747 71 23 561

#	Article	IF	CITATIONS
312	Activation of mixed glia by Aβ-specific Th1 and Th17 cells and its regulation by Th2 cells. Brain, Behavior, and Immunity, 2010, 24, 598-607.	2.0	70
313	Microglia and neuroprotection: From in vitro studies to therapeutic applications. Progress in Neurobiology, 2010, 92, 293-315.	2.8	226
314	Multivariable network associated with cognitive decline and dementia. Neurobiology of Aging, 2010, 31, 257-269.	1.5	37
315	Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-1±-dependent. Neurobiology of Aging, 2010, 31, 175-188.	1.5	80
316	Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiology of Aging, 2010, 31, 747-757.	1.5	111
317	Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimer's Research and Therapy, 2010, 2, 1.	3.0	189
318	β-Amyloid1–42 Gene Transfer Model Exhibits Intraneuronal Amyloid, Gliosis, Tau Phosphorylation, and Neuronal Loss. Journal of Biological Chemistry, 2010, 285, 7440-7446.	1.6	53
319	Neuropathological Alterations in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2011, 1, a006189-a006189.	2.9	2,365
320	Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases. Molecular Diagnosis and Therapy, 2011, 15, 83-102.	1.6	25
321	Novel Anti-Inflammatory Compound SEN1176 Alleviates Behavioral Deficits Induced Following Bilateral Intrahippocampal Injection of Aggregated Amyloid-β1-42. Journal of Alzheimer's Disease, 2011, 25, 219-229.	1.2	22
322	B cells and immunosenescence: A focus on IgG+IgDâ^'CD27â^' (DN) B cells in aged humans. Ageing Research Reviews, 2011, 10, 274-284.	5.0	95
323	The Beneficial Role of Vitamin D in Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2011, 26, 511-520.	0.9	30
324	Short amyloid-beta immunogens show strong immunogenicity and avoid stimulating pro-inflammatory pathways in bone marrow-derived dendritic cells from C57BL/6J mice in vitro. Peptides, 2011, 32, 1617-1625.	1.2	8
325	Metabolic, immune, epigenetic, endocrine and phenotypic abnormalities found in individuals with autism spectrum disorders, Down syndrome and Alzheimer disease may be caused by congenital and/or acquired chronic cerebral toxoplasmosis. Research in Autism Spectrum Disorders, 2011, 5, 14-59.	0.8	27
326	Amyloid Hypothesis and Alzheimer's Disease. , 2011, , .		3
327	History of Innate Immunity in Neurodegenerative Disorders. Frontiers in Pharmacology, 2011, 2, 77.	1.6	44
328	The Early Involvement of the Innate Immunity in the Pathogenesis of Lateonset Alzheimers Disease: Neuropathological, Epidemiological and Genetic Evidence. Current Alzheimer Research, 2011, 8, 142-150.	0.7	92
329	Microglial alterations in human Alzheimer's disease following AÎ ² 42 immunization. Neuropathology and Applied Neurobiology, 2011, 37, 513-524.	1.8	88

#	Article	IF	CITATIONS
330	Cytokines and neuronal channels: A molecular basis for age-related decline of neuronal function?. Experimental Gerontology, 2011, 46, 199-206.	1.2	35
331	Inflammation, mitochondria, and the inhibition of adult neurogenesis. Journal of Neuroscience Research, 2011, 89, 1989-1996.	1.3	90
332	Does a Pro-Inflammatory Process Precede Alzheimers Disease and Mild Cognitive Impairment?. Current Alzheimer Research, 2011, 8, 164-174.	0.7	88
333	Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD. Current Alzheimer Research, 2011, 8, 34-58.	0.7	69
334	Correlation between Cognitive Functions and Nitric Oxide Levels in Patients with Dementia. Clinical EEG and Neuroscience, 2011, 42, 190-194.	0.9	8
335	Effect of growth hormone and melatonin on the brain: from molecular mechanisms to structural changes. Hormone Molecular Biology and Clinical Investigation, 2011, 7, 337-350.	0.3	2
336	Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte–endothelial interactions. Journal of Leukocyte Biology, 2010, 89, 539-556.	1.5	136
337	Pathways towards an effective immunotherapy for Parkinson's disease. Expert Review of Neurotherapeutics, 2011, 11, 1703-1715.	1.4	29
338	Reactive Oxygen Species and Inhibitors of Inflammatory Enzymes, NADPH Oxidase, and iNOS in Experimental Models of Parkinson's Disease. Mediators of Inflammation, 2012, 2012, 1-16.	1.4	83
339	Role of Prostaglandins in Neuroinflammatory and Neurodegenerative Diseases. Mediators of Inflammation, 2012, 2012, 1-13.	1.4	67
340	Simple Synthesis of Modafinil Derivatives and Their Anti-inflammatory Activity. Molecules, 2012, 17, 10446-10458.	1.7	29
341	Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia. Journal of Alzheimer's Disease, 2012, 33, 45-53.	1.2	106
342	Inflammation and Adaptive Immunity in Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009381-a009381.	2.9	221
343	Inflammation in Alzheimer DiseaseA Brief Review of the Basic Science and Clinical Literature. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006346-a006346.	2.9	786
344	Mitochondrial Dysfunction and Immune Activation are Detectable in Early Alzheimer's Disease Blood. Journal of Alzheimer's Disease, 2012, 30, 685-710.	1.2	141
345	Aging-related changes in neuroimmune-endocrine function: Implications for hippocampal-dependent cognition. Hormones and Behavior, 2012, 62, 219-227.	1.0	66
346	Microglial activation in healthy aging. Neurobiology of Aging, 2012, 33, 1067-1072.	1.5	125
347	Astrocytes in aged nonhuman primate brain gray matter synthesize excess hyaluronan. Neurobiology of Aging, 2012, 33, 830.e13-830.e24.	1.5	61

#	Article	IF	CITATIONS
348	AGEs–RAGE mediated up-regulation of connexin43 in activated human microglial CHME-5 cells. Neurochemistry International, 2012, 60, 640-651.	1.9	32
349	Age related changes in microglial phenotype vary between CNS regions: Grey versus white matter differences. Brain, Behavior, and Immunity, 2012, 26, 754-765.	2.0	194
350	The immunology of neurodegeneration. Journal of Clinical Investigation, 2012, 122, 1156-1163.	3.9	187
351	Adhesive Properties and Inflammatory Potential of Citrullinated Myelin Basic Protein Peptide 45–89. Neurochemical Research, 2012, 37, 1959-1966.	1.6	11
352	Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade. International Journal of Alzheimer's Disease, 2012, 2012, 1-9.	1.1	67
353	A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines. Scientific World Journal, The, 2012, 2012, 1-15.	0.8	626
354	The association between systemic inflammation and cognitive performance in the elderly: the Sydney Memory and Ageing Study. Age, 2012, 34, 1295-1308.	3.0	159
355	Microglial TNF-α-Dependent Elevation of MHC Class I Expression on Brain Endothelium Induced by Amyloid-Beta Promotes T Cell Transendothelial Migration. Neurochemical Research, 2013, 38, 2295-2304.	1.6	48
356	The Role of Beta-Adrenergic Receptor Blockers in Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 427-439.	0.9	24
357	Down-regulation of microglial activity attenuates axotomized nigral dopaminergic neuronal cell loss. BMC Neuroscience, 2013, 14, 112.	0.8	8
358	Anti-neuroinflammatory agents for the treatment of Alzheimer's disease. Future Medicinal Chemistry, 2013, 5, 1559-1571.	1.1	26
359	Variant of <i>TREM2</i> Associated with the Risk of Alzheimer's Disease. New England Journal of Medicine, 2013, 368, 107-116.	13.9	2,085
360	Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model. Neurobiology of Aging, 2013, 34, 1355-1368.	1.5	8
361	Neuroimmune Modulation of Synaptic Function. , 2013, , 65-94.		1
362	Review: Experimental manipulations of microglia in mouse models of <scp>A</scp> lzheimer's pathology: activation reduces amyloid but hastens tau pathology. Neuropathology and Applied Neurobiology, 2013, 39, 69-85.	1.8	52
363	Review: Activation patterns of microglia and their identification in the human brain. Neuropathology and Applied Neurobiology, 2013, 39, 3-18.	1.8	792
364	Systemic immune system alterations in early stages of Alzheimer's disease. Journal of Neuroimmunology, 2013, 256, 38-42.	1.1	99
365	Microglia actions in Alzheimer's disease. Acta Neuropathologica, 2013, 126, 461-477.	3.9	247

#	Article	IF	CITATIONS
366	Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. Brain, 2013, 136, 2677-2696.	3.7	234
367	Administration of Glucosylceramide Ameliorated the Memory Impairment in Aged Mice. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10.	0.5	7
368	Role of Scavenger Receptors in Glia-Mediated Neuroinflammatory Response Associated with Alzheimer's Disease. Mediators of Inflammation, 2013, 2013, 1-11.	1.4	22
369	Endothelin-1–Induced Endoplasmic Reticulum Stress in Disease. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 163-172.	1.3	18
370	IFN-γ Production by Amyloid β–Specific Th1 Cells Promotes Microglial Activation and Increases Plaque Burden in a Mouse Model of Alzheimer's Disease. Journal of Immunology, 2013, 190, 2241-2251.	0.4	247
371	Bindarit, Inhibitor of CCL2 Synthesis, Protects Neurons Against Amyloid-β-Induced Toxicity. Journal of Alzheimer's Disease, 2013, 38, 281-293.	1.2	32
372	Amniotic Fluid Stem Cells with Low Î ³ -Interferon Response Showed Behavioral Improvement in Parkinsonism Rat Model. PLoS ONE, 2013, 8, e76118.	1.1	11
373	Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation. Frontiers in Cellular Neuroscience, 2013, 7, 22.	1.8	197
374	The Triggering Receptor Expressed on Myeloid Cells 2: "TREM-ming―the Inflammatory Component Associated with Alzheimer's Disease. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-8.	1.9	36
375	T-Cells Show Increased Production of Cytokines and Activation Markers in Alzheimer's Disease. Brain Disorders & Therapy, 2014, 03, .	0.1	8
377	Vaccination induced changes in pro-inflammatory cytokine levels as an early putative biomarker for cognitive improvement in a transgenic mouse model for Alzheimer disease. Human Vaccines and Immunotherapeutics, 2014, 10, 2024-2031.	1.4	6
378	Latest Study on the Relationship between Pathological Process of Inflammatory Injury and the Syndrome of Spleen Deficiency and Fluid Retention in Alzheimer's Disease. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-7.	0.5	12
379	Protein markers of cerebrovascular disruption of neurovascular unit: immunohistochemical and imaging approaches. Reviews in the Neurosciences, 2014, 25, 481-507.	1.4	27
380	Potential Therapeutic Strategies for Alzheimer's Disease Targeting or Beyond <i>β</i> -Amyloid: Insights from Clinical Trials. BioMed Research International, 2014, 2014, 1-22.	0.9	61
381	Elevated CNS Inflammation in Patients with Preclinical Alzheimer's Disease. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 30-33.	2.4	74
382	Immunomodulatory Therapeutics. , 2014, , 547-567.		Ο
383	Microglial pathology. Acta Neuropathologica Communications, 2014, 2, 142.	2.4	252
384	Alzheimer Disease and Cellular Mechanisms of Memory Storage. Journal of Neuropathology and Experimental Neurology, 2014, 73, 192-205.	0.9	17

#	Article	IF	CITATIONS
385	Respiratory infection promotes T cell infiltration and amyloid-β deposition in APP/PS1 mice. Neurobiology of Aging, 2014, 35, 109-121.	1.5	111
386	Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochemical Pharmacology, 2014, 88, 565-572.	2.0	60
387	Modulation of inflammation in transgenic models of Alzheimer's disease. Journal of Neuroinflammation, 2014, 11, 25.	3.1	99
388	Microglial dysfunction in brain aging and Alzheimer's disease. Biochemical Pharmacology, 2014, 88, 594-604.	2.0	469
389	The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1115-1136.	1.2	77
390	Small Molecule p75NTR Ligands Reduce Pathological Phosphorylation and Misfolding of Tau, Inflammatory Changes, Cholinergic Degeneration, and Cognitive Deficits in AβPPL/S Transgenic Mice. Journal of Alzheimer's Disease, 2014, 42, 459-483.	1.2	75
392	Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. Journal of Neuroinflammation, 2014, 11, 120.	3.1	89
393	Longitudinal follow-up of autophagy and inflammation in brain of APPswePS1dE9 transgenic mice. Journal of Neuroinflammation, 2014, 11, 139.	3.1	86
394	Human CNS immune senescence and neurodegeneration. Current Opinion in Immunology, 2014, 29, 93-96.	2.4	73
395	The impact of neuroimmune changes on development of amyloid pathology; relevance to <scp>A</scp> lzheimer's disease. Immunology, 2014, 141, 292-301.	2.0	56
396	Type 2 Diabetes and Inammation. , 2014, , 153-160.		0
397	Aspirin and anti-inflammatory drugs for the prevention of dementia. The Cochrane Library, 2015, , .	1.5	2
398	Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 48, 319-353.	1.2	202
399	Gene Expression Profiling in the APP/PS1KI Mouse Model of Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 50, 397-409.	1.2	12
400	Expression of HLA-DR, CD80, and CD86 inÂHealthy Aging and Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 177-184.	1.2	23
401	Changes of gene expression of Gal3, Hsp27, Lcn2, and Timp1 in rat substantia nigra following medial forebrain bundle transection using a candidate gene microarray. Journal of Chemical Neuroanatomy, 2015, 66-67, 10-18.	1.0	6
402	T Cells—Protective or Pathogenic in Alzheimer's Disease?. Journal of NeuroImmune Pharmacology, 2015, 10, 547-560.	2.1	42
403	Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer's disease lacking functional B and T cells. Acta Neuropathologica Communications, 2015, 3, 71.	2.4	56

# 404	ARTICLE Immune dysregulation and cognitive vulnerability in the aging brain: Interactions of microglia, IL-1Î ² , BDNF and synaptic plasticity. Neuropharmacology, 2015, 96, 11-18.	IF 2.0	CITATIONS 213
405	Migration of blood cells to β-amyloid plaques in Alzheimer's disease. Experimental Gerontology, 2015, 65, 8-15.	1.2	76
406	Neuroinflammation in the normal aging hippocampus. Neuroscience, 2015, 309, 84-99.	1.1	269
407	Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathologica Communications, 2015, 3, 8.	2.4	127
408	Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. Schizophrenia Research, 2015, 161, 4-18.	1.1	166
409	Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophrenia Research, 2015, 161, 102-112.	1.1	268
410	Common mechanisms involved in Alzheimer's disease and type 2 diabetes: a key role of chronic bacterial infection and inflammation. Aging, 2016, 8, 575-588.	1.4	77
411	Imaging of Leukocyte Trafficking in Alzheimer's Disease. Frontiers in Immunology, 2016, 7, 33.	2.2	36
412	Modulating Role of TTR in A^2 Toxicity, from Health to Disease. , 0, , .		1
413	Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors. Scientific Reports, 2016, 5, 18286.	1.6	37
414	Glial Cells in Health and Disease of the CNS. Advances in Experimental Medicine and Biology, 2016, , .	0.8	9
415	Age-Dependent Changes in the Activation and Regulation of Microglia. Advances in Experimental Medicine and Biology, 2016, 949, 205-226.	0.8	45
416	Inhomogeneous distribution of Ibaâ€1 characterizes microglial pathology in Alzheimer's disease. Glia, 2016, 64, 1562-1572.	2.5	81
417	Do Microglia Default on Network Maintenance in Alzheimer's Disease?. Journal of Alzheimer's Disease, 2016, 51, 657-669.	1.2	17
418	Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neuroscience and Biobehavioral Reviews, 2016, 68, 547-562.	2.9	114
419	<i>Rhodiola rosea</i> L. and Alzheimer's Disease: From Farm to Pharmacy. Phytotherapy Research, 2016, 30, 532-539.	2.8	68
420	Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease. Progress in Neurobiology, 2016, 144, 142-157.	2.8	85

421	T-cell brain infiltration and immature antigen-presenting cells in transgenic models of Alzheimer's	2.0	191
	disease-like cerebral amyloidosis. Brain, Behavior, and Immunity, 2016, 54, 211-225.	2.0	191

#	Article	IF	CITATIONS
422	Intranasal brain delivery of cationic nanoemulsion-encapsulated TNFα siRNA in prevention of experimental neuroinflammation. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 987-1002.	1.7	83
423	Microglia in dementia with Lewy bodies. Brain, Behavior, and Immunity, 2016, 55, 191-201.	2.0	51
424	Linking T cells to Alzheimer's disease: from neurodegeneration to neurorepair. Current Opinion in Pharmacology, 2016, 26, 67-73.	1.7	30
425	Altered Neuroinflammation and Behavior after Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease. Journal of Neurotrauma, 2016, 33, 625-640.	1.7	42
426	Polarization of microglia and its role in bacterial sepsis. Journal of Neuroimmunology, 2017, 303, 90-98.	1.1	43
427	T cell responses in the central nervous system. Nature Reviews Immunology, 2017, 17, 179-194.	10.6	219
428	Microglia activation and phagocytosis: relationship with aging and cognitive impairment in the rhesus monkey. GeroScience, 2017, 39, 199-220.	2.1	90
429	Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease. Neuroscience, 2017, 356, 44-51.	1.1	16
431	The hypothesis that Helicobacter pylori predisposes to Alzheimer's disease is biologically plausible. Scientific Reports, 2017, 7, 7817.	1.6	24
432	Centella asiatica, an Ayurvedic Medicinal Plant, Prevents the Major Neurodegenerative and Neurotoxic Mechanisms Associated with Cognitive Impairment. Medicinal and Aromatic Plants of the World, 2017, , 3-48.	0.1	3
433	Reduced cuprizone-induced cerebellar demyelination in mice with astrocyte-targeted production of IL-6 is associated with chronically activated, but less responsive microglia. Journal of Neuroimmunology, 2017, 310, 97-102.	1.1	18
434	High-fat diet and aging interact to produce neuroinflammation and impair hippocampal- and amygdalar-dependent memory. Neurobiology of Aging, 2017, 58, 88-101.	1.5	138
435	Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain, 2017, 140, 184-200.	3.7	184
436	Microglia show altered morphology and reduced arborization in human brain during aging and <scp>A</scp> lzheimer's disease. Brain Pathology, 2017, 27, 795-808.	2.1	174
437	Imaging Approaches to Cerebral Cortex Pathology. , 2017, , 57-80.		0
438	Neuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimer's disease. Behavioural Brain Research, 2017, 322, 269-279.	1.2	55
439	Neuroglia as targets for drug delivery systems: A review. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 667-679.	1.7	20
440	TLR4 is a link between diabetes and Alzheimer's disease. Behavioural Brain Research, 2017, 316, 234-244.	1.2	96

		CITATION REPORT		
#	Article		IF	CITATIONS
441	The blood-brain barrier in Alzheimer's disease. Neurobiology of Disease, 2017, 107, 41-5	6.	2.1	454
442	Fate of microglia during HIVâ€1 infection: From activation to senescence?. Glia, 2017, 6	5, 431-446.	2.5	78
443	Changes in neocortical and hippocampal microglial cells during hibernation. Brain Struct Function, 2017, 223, 1881-1895.	ure and	1.2	8
444	Similarity and Differences in Inflammation-Related Characteristics of the Peripheral Imm Patients with Parkinson's and Alzheimer's Diseases. International Journal of Mole 18, 2633.	une System of ecular Sciences, 2017,	1.8	39
445	Plasma Exosomes Spread and Cluster Around β-Amyloid Plaques in an Animal Model of A Disease. Frontiers in Aging Neuroscience, 2017, 9, 12.	Alzheimer's	1.7	57
446	Doublecortin expression in CD8+ Tâ€cells and microglia at sites of amyloidâ€Î² plaques: shaping plaque pathology?. Alzheimer's and Dementia, 2018, 14, 1022-1037.	A potential role in	0.4	36
447	Novel targets in Alzheimer's disease: A special focus on microglia. Pharmacological R 130, 402-413.	lesearch, 2018,	3.1	46
448	Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration. Cell Death and Disease, 2018, 9, 120.		2.7	79
449	Extravascular CD3+ T Cells in Brains of Alzheimer Disease Patients Correlate with Tau bu Amyloid Pathology: An Immunohistochemical Study. Neurodegenerative Diseases, 2018		0.8	119
450	Cognitive Science and Health Bioinformatics. SpringerBriefs in Applied Sciences and Tec	hnology, 2018,	0.2	0
451	In Thai Nationals, the ApoE4 Allele Affects Multiple Domains of Neuropsychological, Biob and Social Functioning Thereby Contributing to Alzheimer's Disorder, while the Apol Against Neuropsychiatric Symptoms and Psychosocial Deficits. Molecular Neurobiology, 6449-6462.	E3 Allele Protects	1.9	13
452	Insilico Binding Studies of Resveratrol for Protective Effects in Neurodegeneration Using Receptor 3B as Target Model. SpringerBriefs in Applied Sciences and Technology, 2018,	Glutamate , 83-96.	0.2	0
453	Decreased microglial numbers in Vav1-Cre + :dicer knock-out mice suggest a second sou microglia beyond yolk sac macrophages. Annals of Anatomy, 2018, 218, 190-198.	irce of	1.0	11
454	Principles for central nervous system inflammation research: A call for a consortium app Alzheimer's and Dementia, 2018, 14, 1553-1559.	roach.	0.4	18
455	Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?. Bio Journal, 2018, 41, 21-33.	medical	1.4	262
456	Increased quinolinic acid in peripheral mononuclear cells in Alzheimer's dementia. Eu of Psychiatry and Clinical Neuroscience, 2018, 268, 493-500.	Iropean Archives	1.8	16
457	Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impa Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 123-131.	irment.	2.5	76
458	Markers of microglia in post-mortem brain samples from patients with Alzheimer's d systematic review. Molecular Psychiatry, 2018, 23, 177-198.	isease: a	4.1	331

#	Article	IF	CITATIONS
459	Imaging microglial activation and amyloid burden in amnestic mild cognitive impairment. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1885-1895.	2.4	29
460	Defining Microglial Phenotypes in Alzheimer's Disease. , 2018, , .		0
461	Imaging and Molecular Mechanisms of Alzheimer's Disease: A Review. International Journal of Molecular Sciences, 2018, 19, 3702.	1.8	45
462	Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice. Journal of Neuroinflammation, 2018, 15, 274.	3.1	89
463	Peripheral immune system in aging and Alzheimer's disease. Molecular Neurodegeneration, 2018, 13, 51.	4.4	143
464	Inflammation as a central mechanism in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 575-590.	1.8	1,254
465	Salivary biomarkers for the diagnosis andÂmonitoring of neurological diseases. Biomedical Journal, 2018, 41, 63-87.	1.4	122
466	Dendritic Cells as an Alternate Approach for Treatment of Neurodegenerative Disorders. Cellular and Molecular Neurobiology, 2018, 38, 1207-1214.	1.7	12
467	Royal Jelly Attenuates LPS-Induced Inflammation in BV-2 Microglial Cells through Modulating NF- <i>iº</i> B and p38/JNK Signaling Pathways. Mediators of Inflammation, 2018, 2018, 1-11.	1.4	54
468	Immunosenescence – the role in the immunotherapy of older population. Bratislava Medical Journal, 2018, 119, 217-220.	0.4	5
469	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91, e867-e877.	1.5	207
470	Neuroinflammation: Microglia and T Cells Get Ready to Tango. Frontiers in Immunology, 2017, 8, 1905.	2.2	257
471	BALB/c mice infected with DENV-2 strain 66985 by the intravenous route display injury in the central nervous system. Scientific Reports, 2018, 8, 9754.	1.6	17
472	Longitudinal chemokine profile expression in a blood-brain barrier model from Alzheimer transgenic versus wild-type mice. Journal of Neuroinflammation, 2018, 15, 182.	3.1	11
473	Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model. PLoS ONE, 2018, 13, e0201232.	1.1	8
474	Dual Effects of Human Placenta-Derived Neural Cells on Neuroprotection and the Inhibition of Neuroinflammation in a Rodent Model of Parkinson's Disease. Cell Transplantation, 2018, 27, 814-830.	1.2	39
475	Roles for the adaptive immune system in Parkinson's and Alzheimer's diseases. Current Opinion in Immunology, 2019, 59, 115-120.	2.4	38
476	Blockade of α4 integrins reduces leukocyte–endothelial interactions in cerebral vessels and improves memory in a mouse model of Alzheimer's disease. Scientific Reports, 2019, 9, 12055.	1.6	44

#	Article	IF	CITATIONS
477	Animal models of olfactory dysfunction in neurodegenerative diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 164, 431-452.	1.0	12
478	Spatial analysis of thickness changes in ten retinal layers of Alzheimer's disease patients based on optical coherence tomography. Scientific Reports, 2019, 9, 13000.	1.6	28
479	<p>Long-term icariin treatment ameliorates cognitive deficits via CD4⁺ T cell-mediated immuno-inflammatory responses in APP/PS1 mice</p> . Clinical Interventions in Aging, 2019, Volume 14, 817-826.	1.3	21
480	Immune Signaling in Neurodegeneration. Immunity, 2019, 50, 955-974.	6.6	217
481	Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease. Journal of Neuroinflammation, 2019, 16, 74.	3.1	125
482	The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. Frontiers in Pharmacology, 2019, 10, 200.	1.6	82
483	Neuroimmune interactions in Alzheimer's disease—New frontier with old challenges?. Progress in Molecular Biology and Translational Science, 2019, 168, 183-201.	0.9	12
484	Prominent microglial activation in cortical white matter is selectively associated with cortical atrophy in primary progressive aphasia. Neuropathology and Applied Neurobiology, 2019, 45, 216-229.	1.8	15
485	Dystrophic microglia in lateâ€onset Alzheimer's disease. Glia, 2020, 68, 845-854.	2.5	99
486	The role of commensal microflora-induced T cell responses in glaucoma neurodegeneration. Progress in Brain Research, 2020, 256, 79-97.	0.9	21
487	Construction of a 3D brain extracellular matrix model to study the interaction between microglia and T cells in coâ€culture. European Journal of Neuroscience, 2021, 53, 4034-4050.	1.2	6
488	Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients. Frontiers in Aging Neuroscience, 2020, 12, 272.	1.7	17
489	Shexiang Baoxin Pill, a Traditional Chinese Herbal Formula, Rescues the Cognitive Impairments in APP/PS1 Transgenic Mice. Frontiers in Pharmacology, 2020, 11, 1045.	1.6	7
490	The pleiotropic role of p53 in functional/dysfunctional neurons: focus on pathogenesis and diagnosis of Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 160.	3.0	26
491	Allosterism of Nicotinic Acetylcholine Receptors: Therapeutic Potential for Neuroinflammation Underlying Brain Trauma and Degenerative Disorders. International Journal of Molecular Sciences, 2020, 21, 4918.	1.8	10
492	CD8 ⁺ T cells are increased in the subventricular zone with physiological and pathological aging. Aging Cell, 2020, 19, e13198.	3.0	16
493	Exploring the genetic relationship between hearing impairment and Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12108.	1.2	13
494	Aging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe?. Frontiers in Aging Neuroscience, 2020, 12, 572090.	1.7	78

#	Article	IF	CITATIONS
495	Heat Shock Proteins, a Key Modulator of Neuroinflammation in Alzheimer's Disease. Heat Shock Proteins, 2020, , 89-145.	0.2	1
496	Target Dysbiosis of Gut Microbes as a Future Therapeutic Manipulation in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 544235.	1.7	38
497	Synaptic Loss in Alzheimer's Disease: Mechanistic Insights Provided by Two-Photon in vivo Imaging of Transgenic Mouse Models. Frontiers in Cellular Neuroscience, 2020, 14, 592607.	1.8	47
498	Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. The Cochrane Library, 2020, 2020, CD011459.	1.5	33
499	CD8+ T-cells infiltrate Alzheimer's disease brains and regulate neuronal- and synapse-related gene expression in APP-PS1 transgenic mice. Brain, Behavior, and Immunity, 2020, 89, 67-86.	2.0	112
500	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clinical Cancer Research, 2020, 26, 5232-5245.	3.2	52
501	Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Molecular Neurodegeneration, 2020, 15, 32.	4.4	57
502	Inflammation in Neurological Disorders: The Thin Boundary Between Brain and Periphery. Antioxidants and Redox Signaling, 2020, 33, 191-210.	2.5	68
503	The role of the immune system in driving neuroinflammation. Brain and Neuroscience Advances, 2020, 4, 239821281990108.	1.8	42
504	Alzheimer's Disease: From Amyloid to Autoimmune Hypothesis. Neuroscientist, 2020, 26, 455-470.	2.6	17
505	Peripheral cytokine and fatty acid associations with neuroinflammation in AD and aMCI patients: An exploratory study. Brain, Behavior, and Immunity, 2020, 87, 679-688.	2.0	19
506	Diclofenac reduces the risk of Alzheimer's disease: a pilot analysis of NSAIDs in two US veteran populations. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093567.	1.5	27
507	Nrf2 Suppresses Oxidative Stress and Inflammation in <i>App</i> Knock-In Alzheimer's Disease Model Mice. Molecular and Cellular Biology, 2020, 40, .	1.1	98
508	Erosion of Gene Co-expression Networks Reveal Deregulation of Immune System Processes in Late-Onset Alzheimer's Disease. Frontiers in Neuroscience, 2020, 14, 228.	1.4	6
509	Accumulation of neurofibrillary tangles and activated microglia is associated with lower neuron densities in the aphasic variant of Alzheimer's disease. Brain Pathology, 2021, 31, 189-204.	2.1	36
510	Low levels of salivary lactoferrin may affect oral dysbiosis and contribute to Alzheimer's disease: A hypothesis. Medical Hypotheses, 2021, 146, 110393.	0.8	21
511	Microglia is associated with p-Tau aggregates in the olfactory bulb of patients with neurodegenerative diseases. Neurological Sciences, 2021, 42, 1473-1482.	0.9	8
512	Impact of Tau on Neurovascular Pathology in Alzheimer's Disease. Frontiers in Neurology, 2020, 11, 573324.	1.1	24

#	Article	IF	CITATIONS
513	Molecular Changes in Circulating microRNAs' Expression and Oxidative Stress in Adults with Mild Cognitive Impairment: A Biochemical and Molecular Study. Clinical Interventions in Aging, 2021, Volume 16, 57-70.	1.3	16
514	Role of Adaptive Immune and Impacts of Risk Factors on Adaptive Immune in Alzheimer's Disease: Are Immunotherapies Effective or Off-Target?. Neuroscientist, 2022, 28, 254-270.	2.6	9
515	Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer's disease. Brain Research, 2021, 1753, 147264.	1.1	5
516	Neuroinflammation in Alzheimer's disease and beneficial action of luteolin. BioFactors, 2021, 47, 207-217.	2.6	21
517	Exploring Potential of Alkaloidal Phytochemicals Targeting Neuroinflammatory Signaling of Alzheimer's Disease. Current Pharmaceutical Design, 2021, 27, 357-366.	0.9	11
518	Common Peripheral Immunity Mechanisms in Multiple Sclerosis and Alzheimer's Disease. Frontiers in Immunology, 2021, 12, 639369.	2.2	33
519	Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders. Frontiers in Neuroscience, 2021, 15, 656921.	1.4	16
520	Modification of Glial Cell Activation through Dendritic Cell Vaccination: Promises for Treatment of Neurodegenerative Diseases. Journal of Molecular Neuroscience, 2021, 71, 1410-1424.	1.1	12
521	Inflammation, Nitro-Oxidative Stress, Impaired Autophagy, and Insulin Resistance as a Mechanistic Convergence Between Arterial Stiffness and Alzheimer's Disease. Frontiers in Molecular Biosciences, 2021, 8, 651215.	1.6	16
522	Microglial Adenosine Receptors: From Preconditioning to Modulating the M1/M2 Balance in Activated Cells. Cells, 2021, 10, 1124.	1.8	22
523	Biomarkers and Their Implications in Alzheimer's Disease: A Literature Review. Exploratory Research and Hypothesis in Medicine, 2021, 000, 000-000.	0.1	5
524	Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy. Frontiers in Aging Neuroscience, 2021, 13, 658605.	1.7	11
525	Alzheimer's Disease Genetics: A Dampened Microglial Response?. Neuroscientist, 2023, 29, 245-263.	2.6	11
526	Quantitative, structural and molecular changes in neuroglia of aging mammals: A review. European Journal of Histochemistry, 2021, 65, .	0.6	7
527	Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer's Disease. Current Neuropharmacology, 2021, 19, 908-924.	1.4	29
528	CSF and Plasma Cholinergic Markers in Patients With Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 704583.	1.7	14
529	Vascular contributions to cognitive impairment and dementia: the emerging role of 20-HETE. Clinical Science, 2021, 135, 1929-1944.	1.8	11
530	Trends in incidence of dementia among patients with rheumatoid arthritis: A population-based cohort study. Seminars in Arthritis and Rheumatism, 2021, 51, 853-857.	1.6	11

#	Article	IF	CITATIONS
531	The Impact of β-1,4-Galactosyltransferase V on Microglial Function. Frontiers in Cellular Neuroscience, 2021, 15, 723308.	1.8	4
532	Altered theta rhythm and hippocampal-cortical interactions underlie working memory deficits in a hyperglycemia risk factor model of Alzheimer's disease. Communications Biology, 2021, 4, 1036.	2.0	19
533	Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus. Nature Reviews Neurology, 2021, 17, 689-701.	4.9	169
534	Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment. , 2022, 231, 107979.		26
535	Sources and triggers of oxidative damage in neurodegeneration. Free Radical Biology and Medicine, 2021, 173, 52-63.	1.3	26
536	Glioblastoma as an age-related neurological disorder in adults. Neuro-Oncology Advances, 2021, 3, vdab125.	0.4	30
537	Mechanistic role of boswellic acids in Alzheimer's disease: Emphasis on anti-inflammatory properties. Biomedicine and Pharmacotherapy, 2021, 144, 112250.	2.5	23
538	Sex differences in CSF biomarkers of Alzheimer's disease. , 2021, , 107-123.		0
539	Inflammatory Processes Exacerbate Degenerative Neurological Disorders. , 2009, , 117-124.		4
540	Contrasting Effects of Specific Lymphokines on the Survival of Hippocampal Neurons in Culture. Advances in Behavioral Biology, 1992, , 113-122.	0.2	17
541	Neuropathological Correlates of Dementia in Alzheimer's Disease. Cerebral Cortex, 1999, , 513-551.	0.6	3
542	Molecular Pathobiology of Alzheimer's Disease. , 1994, , 209-238.		3
543	Immunoneurology: A Serum Protein Afferent Limb to the CNS. Advances in Experimental Medicine and Biology, 1990, 274, 345-370.	0.8	3
545	Inflammatory Mediators in Alzheimer's Disease. , 1997, , 177-198.		11
546	Roles of CNS Macrophages in Neurodegeneration. , 1998, , 1-59.		9
547	Inflammatory Markers in Chronic Neurodegenerative Disorders with Emphasis on Alzheimer's Disease. , 1998, , 61-90.		10
549	The Involvement of $A\hat{l}^2$ in the Neuroinflammatory Response. , 2007, , 52-82.		1
550	Complement, neuroinflammation and neuronal degeneration in Alzheimer disease. , 2001, , 15-20.		1

# 551	ARTICLE Neurodegenerative Alzheimer-like Pathology in PDAPP 717V → F Transgenic Mice. Research and Perspectives in Alzheimer's Disease, 1997, , 105-119.	lF 0.1	CITATIONS
552	Elucidating Molecular Mechanisms of Alzheimer's Disease in Microglial Cultures. , 2002, , 25-44.		12
553	Effects of Cerebrolysinâ,,¢ on amyloid-β deposition in a transgenic model of Alzheimer's disease. Journal of Neural Transmission Supplementum, 2002, , 327-336.	0.5	40
554	Mechanisms of synaptic pathology in Alzheimer's disease. Journal of Neural Transmission Supplementum, 1998, 53, 147-158.	0.5	36
555	Alzheimer disease and neuroinflammation. , 2000, 59, 53-57.		94
556	Therapeutic strategies based on immunological hypotheses of Alzheimer's disease. Journal of Neural Transmission Supplementum, 1998, 54, 175-186.	0.5	1
557	Prevalence of cognitive disorders differs as a function of age in HIV virus infection. Aids, 2004, , 11-18.	1.0	31
560	The serpin-enzyme complex (SEC) receptor mediates the neutrophil chemotactic effect of alpha-1 antitrypsin-elastase complexes and amyloid-beta peptide Journal of Clinical Investigation, 1992, 90, 1150-1154.	3.9	67
561	Chronic Apocynin Treatment Attenuates Beta Amyloid Plaque Size and Microglial Number in hAPP(751)SL Mice. PLoS ONE, 2011, 6, e20153.	1.1	44
562	Alzheimer's Disease Related Markers, Cellular Toxicity and Behavioral Deficits Induced Six Weeks after Oligomeric Amyloid-β Peptide Injection in Rats. PLoS ONE, 2013, 8, e53117.	1.1	96
563	Characterization of Novel Src Family Kinase Inhibitors to Attenuate Microgliosis. PLoS ONE, 2015, 10, e0132604.	1.1	15
564	Long-term administration of melatonin attenuates neuroinflammation in the aged mouse brain. EXCLI Journal, 2018, 17, 634-646.	0.5	25
565	Systemic and CNS Inflammation Crosstalk: Implications for Alzheimer's Disease. Current Alzheimer Research, 2019, 16, 559-574.	0.7	72
566	Common Pathological Mechanisms and Risk Factors for Alzheimer's Disease and Type-2 Diabetes: Focus on Inflammation. Current Alzheimer Research, 2019, 16, 986-1006.	0.7	7
567	Type 2 Diabetes: Local Inflammation and Direct Effect of Bacterial Toxic Components. The Open Pathology Journal, 2008, 2, 86-95.	1.0	9
568	Inflammation and the pathophysiology of Alzheimer's disease. Dialogues in Clinical Neuroscience, 2000, 2, 233-239.	1.8	5
569	Involvement of blood mononuclear cells in the infertility, age-associated diseases and cancer treatment. World Journal of Stem Cells, 2016, 8, 399.	1.3	4
570	Genetically altered transgenic models of Alzheimer's disease. , 2000, 59, 175-183.		29

#	Article	IF	CITATIONS
571	Organization of Inflammatory Processes in Alzheimer's Disease. Research and Perspectives in Neurosciences, 2000, , 1-7.	0.4	0
572	Glial Hyperactivity During Aging as a Neuroinflammatory Process. Research and Perspectives in Neurosciences, 2000, , 47-56.	0.4	0
574	Microglia. , 2001, , 209-224.		0
575	Role and regulation of early complement activation products in Alzheimer's disease. , 2001, , 67-87.		0
578	Aging and Cognitive Decline: Neuroprotective Strategies. , 2007, , 245-268.		0
579	Neuroinflammation and the Glial Endocannabinoid System. , 2008, , 331-359.		0
580	Phospo-PKCs in Abeta1-42-Specific Human T Cells from Alzheimer's Disease Patients. , 0, , .		0
581	Immune Responses in HIV Infection, Alcoholism, and Aging: A Neuroimaging Perspective. , 2013, , 441-476.		0
582	Neuroprotection Versus Neurotoxicity. , 2014, , 145-172.		2
583	Role of Complements and Immunoglobulins in Alzheimer's Disease. Open Journal of Applied Sciences, 2014, 04, 285-298.	0.2	0
586	Inflammation in the CNS and in Alzheimerâ \in Ms Disease. , 1996, , 147-168.		0
587	Proceso inflamatorio en la enfermedad de Alzheimer. Papel de las citoquinas. , 2014, , 121-156.		0
588	Aging and Microglial Activation in Neurodegenerative Diseases. Oxidative Stress in Applied Basic Research and Clinical Practice, 2016, , 107-131.	0.4	0
589	Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old. Dialogues in Clinical Neuroscience, 2019, 21, 7-19.	1.8	6
590	Insights into T ell dysfunction in Alzheimer's disease. Aging Cell, 2021, 20, e13511.	3.0	39
591	Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases. , 2020, , 335-370.		0
592	Neuroinflammation in Alzheimer's disease continuum. Neurological Sciences and Neurophysiology, 2020, 37, 155.	0.1	1
593	Characterizing the distributions of IDO-1 expressing macrophages/microglia in human and murine brains and evaluating the immunological and physiological roles of IDO-1 in RAW264.7/BV-2 cells. PLoS ONE, 2021, 16, e0258204.	1.1	10

#	Article	IF	CITATIONS
595	Detection of HLA-DR on microglia in the human brain is a function of both clinical and technical factors. American Journal of Pathology, 1990, 136, 1101-14.	1.9	160
596	Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. American Journal of Pathology, 1992, 140, 1389-99.	1.9	124
598	Memory impairments in healthy aging: Role of aging-induced microglial sensitization. , 2010, 1, 212-231.		44
600	Molecular mechanisms of omega-3 fatty acids in the migraine headache. Iranian Journal of Neurology, 2017, 16, 210-217.	0.5	13
601	CD8 T cells are present at low levels in the white matter with physiological and pathological aging. Aging, 2020, 12, 18928-18941.	1.4	0
602	All roads lead to Rome — a review of the potential mechanisms by which exerkines exhibit neuroprotective effects in Alzheimer's disease. Neural Regeneration Research, 2022, 17, 1210.	1.6	12
603	The KEAP1-NRF2 System in Healthy Aging and Longevity. Antioxidants, 2021, 10, 1929.	2.2	44
604	Hydroxysafflor Yellow A Inhibits Aβ1–42-Induced Neuroinflammation by Modulating the Phenotypic Transformation of Microglia via TREM2/TLR4/NF-κB Pathway in BV-2 Cells. Neurochemical Research, 2022, 47, 748-761.	1.6	17
605	Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 85, 457-472.	1.2	6
606	CSF-Derived CD4+ T-Cell Diversity Is Reduced in Patients With Alzheimer Clinical Syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, e1106.	3.1	11
607	Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An inâ€depth exploration of seven established risk factors. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12202.	1.8	12
608	APOE4 confers transcriptomic and functional alterations to primary mouse microglia. Neurobiology of Disease, 2022, 164, 105615.	2.1	22
609	CD8 ⁺ T cells are present at low levels in the white matter with physiological and pathological aging. Aging, 2020, 12, 18928-18941.	1.4	6
610	The P522R protective variant of PLCG2 promotes the expression of antigen presentation genes by human microglia in an Alzheimer's disease mouse model. Alzheimer's and Dementia, 2022, 18, 1765-1778.	0.4	19
611	Prostacyclin Promotes Degenerative Pathology in a Model of Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2022, 16, 769347.	1.8	1
612	Microglia and Macrophages in Neuroprotection, Neurogenesis, and Emerging Therapies for Stroke. Cells, 2021, 10, 3555.	1.8	20
613	Decreased Netrin-1 in Mild Cognitive Impairment and Alzheimer's Disease Patients. Frontiers in Aging Neuroscience, 2021, 13, 762649.	1.7	5
614	Complex Processes Underlying the Dynamic Changes of D-serine Levels in AD Brains. Current Alzheimer Research, 2022, 19, 485-493.	0.7	3

	CITATION R	EPORT	
#	Article	IF	Citations
615	The Role of Immunity in Alzheimer's Disease. Advanced Biology, 2022, , 2101166.	1.4	10
625	Priming of microglia by type II interferon is lasting and resistant to modulation by interleukin-10 in situ. Journal of Neuroimmunology, 2022, 368, 577881.	1.1	3
626	Single-Cell Analysis of the Peripheral Immune Landscape in Alzheimer's Disease Reveals a Distinct Adaptive Immune Signature. SSRN Electronic Journal, 0, , .	0.4	0
627	Neuroimmune contributions to Alzheimer's disease: a focus on human data. Molecular Psychiatry, 2022, 27, 3164-3181.	4.1	20
628	Acquired immunity and Alzheimer's disease. Journal of Biomedical Research, 2023, 37, 15.	0.7	0
629	Phenylethanoid Glycosides of Cistanche Improve Learning and Memory Disorders in APP/PS1 Mice by Regulating Clial Cell Activation and Inhibiting TLR4/NF-κB Signaling Pathway. NeuroMolecular Medicine, 2023, 25, 75-93.	1.8	3
630	Spontaneous and induced adaptive immune responses in Alzheimer's disease: new insights into old observations. Current Opinion in Immunology, 2022, 77, 102233.	2.4	8
631	Crossing borders in Alzheimer's disease: A T cell's perspective. Advanced Drug Delivery Reviews, 2022, 188, 114398.	6.6	13
632	IMMUNOSENESCENCE-RELATED DISEASES IN THE ELDERLY. Immunology and Allergy Clinics of North America, 1993, 13, 695-712.	0.7	9
633	Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors. Neural Regeneration Research, 2023, 18, 5.	1.6	4
634	Pomegranate (Punica granatum L.) Attenuates Neuroinflammation Involved in Neurodegenerative Diseases. Foods, 2022, 11, 2570.	1.9	16
635	Forest Biomass as a Promising Source of Bioactive Essential Oil and Phenolic Compounds for Alzheimer's Disease Therapy. International Journal of Molecular Sciences, 2022, 23, 8812.	1.8	1
636	Molecular and histological correlates of cognitive decline across age in male C57BL/6J mice. Brain and Behavior, 2022, 12, .	1.0	7
638	How the immune system shapes neurodegenerative diseases. Trends in Neurosciences, 2022, 45, 733-748.	4.2	17
639	The relationships between neuroglial alterations and neuronal changes in Alzheimer's disease, and the related controversies I: Gliopathogenesis and glioprotection. Journal of Central Nervous System Disease, 2022, 14, 117957352211287.	0.7	1
640	Transcriptomic Profiling Identifies CD8+ T Cells in the Brain of Aged and Alzheimer's Disease Transgenic Mice as Tissue-Resident Memory T Cells. Journal of Immunology, 2022, 209, 1272-1285.	0.4	28
641	Alzheimer's Disease: From Immune Homeostasis to Neuroinflammatory Condition. International Journal of Molecular Sciences, 2022, 23, 13008.	1.8	13
642	The Hidden Role of Non-Canonical Amyloid β Isoforms in Alzheimer's Disease. Cells, 2022, 11, 3421.	1.8	3

#	Article	IF	CITATIONS
643	Interferon Î ³ : a master cytokine in microglia-mediated neural network dysfunction and neurodegeneration. Trends in Neurosciences, 2022, 45, 913-927.	4.2	25
645	Neuroinflammation, immune response and $\hat{I}\pm$ -synuclein pathology: how animal models are helping us to connect dots. Expert Opinion on Drug Discovery, 2023, 18, 13-23.	2.5	1
646	Dual-Specificity Protein Phosphatase 4 (DUSP4) Overexpression Improves Learning Behavior Selectively in Female 5xFAD Mice, and Reduces β-Amyloid Load in Males and Females. Cells, 2022, 11, 3880.	1.8	6
647	LilrB3 is a putative cell surface receptor of APOE4. Cell Research, 2023, 33, 116-130.	5.7	10
648	The neuroimmune axis of Alzheimerâ \in $^{\mathrm{Ms}}$ s disease. Genome Medicine, 2023, 15, .	3.6	59
650	Cornuside, by regulating the <scp>AGEsâ€RAGEâ€lîºBαâ€ERK1</scp> /2 signaling pathway, ameliorates cognitive impairment associated with brain aging. Phytotherapy Research, 0, , .	2.8	1
651	Immune Regulatory Functions of Macrophages and Microglia in Central Nervous System Diseases. International Journal of Molecular Sciences, 2023, 24, 5925.	1.8	4
652	Effects of Current Psychotropic Drugs on Inflammation and Immune System. Advances in Experimental Medicine and Biology, 2023, , 407-434.	0.8	0
653	Effects of intermittent fasting on cognitive health and Alzheimer's disease. Nutrition Reviews, 2023, 81, 1225-1233.	2.6	11
658	Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	49
659	Gut microbiota and circadian rhythm in Alzheimer's disease pathophysiology: a review and hypothesis on their association. , 2023, 9, .		0
661	Role of neuroinflammation in neurodegeneration development. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	62
666	Emerging diagnostics and therapeutics for Alzheimer disease. Nature Medicine, 2023, 29, 2187-2199.	15.2	20
669	Precision Nutrition in Aging and Brain Health. , 2024, , 241-276.		0
670	Role of Vitamins in Alzheimer's Disease 2023 27-42		0

670 Role of Vitamins in Alzheimer's Disease. , 2023, , 27-42.